Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1

Journal of Infectious Diseases

Volumn 187, Issue 4, 2003, Pages 675-678

  Ballou, W Ripley ^a   Reed, Jennifer L ^b   Noble, William ^a   Young, Neal S ^d   Koenig, Scott ^c,e  

^a MEDIMMUNE   (United States)

^b Immunology and Molecular Genetics   (United States)

^c MedImmune   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e Analytical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; MEDI 491; MF 59C.1; PARVOVIRUS B19 VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA ABRASION; CORNEA DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; EMULSION; ERYTHEMA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION PAIN; INJECTION SITE SWELLING; MYALGIA; NORMAL HUMAN; PARVOVIRUS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; VACCINATION; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CAPSID; CAPSID PROTEINS; DOUBLE-BLIND METHOD; HUMANS; IMMUNIZATION SCHEDULE; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; NEUTRALIZATION TESTS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS; POLYSORBATES; SQUALENE; VACCINATION; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0037442784     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/368382     Document Type: Article

References (15)

1. Brown KE, Young NS, Liu JS. Molecular, cellular and clinical aspects of parvovirus B19 infection. Crit Rev Oncol Hematol 1994; 16:1-31.
2. Kelleher JF, Luban NL, Mortimer PP, Kamimura T. Human serum "parvovirus": a specific cause of aplastic crisis in children with hereditary spherocytosis. J Pediatr 1983; 102:720-2.
3. Anand A, Gray ES, Brown T, Clewley JP, Cohen BH. Human parvovirus infection in pregnancy and hydrops fetails. N Engl J Med 1987; 316:183-6.
4. Zuffi E, Manaresi E, Gallinella G, et al. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans. Viral Immunol 2001; 14:151-8.
5. Bostic JR, Brown KE, Young NS, Koenig S. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay. J Infect Dis 1999; 179:619-26.
6. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999; 17:1075-81.
7. Kaijigaya S, Fugii H, Field A, et al. Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci USA 1991; 88:4646-50.
8. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, van Nest G. Design and evaluation of a safe and potent adjuvant for human vaccines. In: Powell MF, Newman MJ, eds. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press, 1995:277-95.
9. Shimomura S, Komatsu N, Frickhofen N, Anderson S, Kajigaya S, Young NS. First continuous propagation of B19 parvovirus in a cell line. Blood 1992; 79:18-24.
10. Komatsu N, Yamamoto M, Fujita H, et al. Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7. Blood 1993; 82:456-64.
11. Ozawa K, Ayub J, Hao YS, Kurtzman G, Shimada T, Young NS. Novel transcription map for the B19 (human) pathogenic parvovirus. J Virol 1987; 61:2395-406.
12. Pass RE, Duliegè A-M, Boppana S, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999; 180:970-5.
13. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: a randomized trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43.
14. Nitayaphan S, Khamboonruang C, Narongrid S, et al. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. Vaccine 2000; 18:1448-55.
15. Selbing A, Josefsson A, Dahle LO, Lindgren R. Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet 1995; 345:660-1.